The Food and Drug Administration found issues at an Indian factory making generic drugs linked to deaths. #FDA #DrugRecalls #MedicationSafety #HealthCare #DrugManufacturing #FDAInspections

Calls for tighter government oversight are justified, yet regulation alone may not suffice in a system vulnerable to corruption

New FDA PreCheck Program to Boost U.S. Drug Manufacturing / cancer, FDA PreCheck, Jennifer Buell, MiNK Therapeutics, OncoDaily, Oncology, U.S. Drug

By Zara Norman/Medill News Service WASHINGTON — John Bailey said he’s saved tens of thousands of dollars over the last decade by relying on a generic prescription to lower his cholesterol. The 68-year...

India’s ace in the hole is mainly generic drug manufacturing, a sub-sector of pharmaceutical manufacturing where it holds over 20% of the market by volume. This translates into manufacturing for over 60,000 brands in 60 distinct categories.

In another effort to boost domestic drug manufacturing, the FDA is piloting fast-track reviews for generics tested and made in US facilities.

Biopharmaceuticals Contract Manufacturing Market is reaching at a CAGR of 5.80 %, Expected to Grow from USD 18.82 Billion to USD 34.99 Billion During 2025 - 2035.

Small Molecule CDMO Market to grow at 3.66% CAGR, reaching USD 119.98 Billion by 2035, driving, size, growth, global trends, competitive analysis and industry outlook 2025-2035.

South Korea's Celltrion has received approval from Health Canada for its biosimilar treatment, Omlyclo, for allergic asthma. The company plans to expand its presence in Canada, with a third manufactur...

(Reuters) -Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country. Companies with more exposure to the UK, the EU, South Korea and Japan are likely on better footing as these countries have secured favorable agreements capping tariffs at around 15%. But with many countries still engaged in trade talks with the U.S., businesses around the world are hedging their decisions pending more clarity on final tariff rates. Here’s what drugmakers are doing to mitigate supply-chain risks and reassure investors: The U.S. drugmaker plans to invest $27 billion to build four new manufacturing facilities over the next five years in the U.S. It aims to announce two of its new site locations this quarter. Johnson & Johnson The drugmaker plans to raise U.S. investments by 25%, totaling $55 billion, over the next four years. It plans to build four plants, including one at Wilson, North Carolina, and another at Tokyo-based Fujifilm Biotechnologies’ manufacturing site in Holly Springs, North Carolina, over the next 10 years. Locations for the other plants remain undisclosed. The Swiss drugmaker said in April it will invest $50 billion in the U.S. over the next five years. A month later, it announced an additional $550 million investment to expand its Indianapolis diagnostics manufacturing hub. The expansion will span Indiana, Pennsylvania, Massachusetts, and California, creating more than 12,000 jobs. 3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads. Roche said in May it plans to invest more than $700 million in a new drug manufacturing facility in Holly Springs, North Carolina. CEO Thomas Schinecker said in July the company had moved around inventories and ramped up production of all the medicines that it already produced in the U.S. in anticipation of tariffs. The Anglo-Swedish drugmaker will invest $50 billion on U.S. manufacturing by 2030. The investment will fund a new drug substance facility in Virginia, its largest single-site global investment, alongside expansions in Maryland, Massachusetts, California, Indiana and Texas. It has already started technology transfers and is managing inventory in 2025 to minimize any tariff hit. Company executives have said the impact would be "very short-lived." The Swiss drugmaker plans to spend $23 billion to build and expand 10 facilities in the U.S. over the next five years. This includes building six new manufacturing plants and expanding its San Diego research and development site, which is expected to create more than 1,000 jobs. The French drugmaker plans to invest at least $20 billion in the U.S. through 2030 to boost manufacturing and research. Sanofi plans to expand its U.S. manufacturing capacity through direct investments in the company’s sites and partnerships with other domestic manufacturers. Chief Financial Officer François Roger said in July the potential tariffs are expected to have a limited impact in 2025, as the company already has inventory in place in the U.S. 3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads. The U.S. drugmaker will invest $2 billion more in its existing manufacturing plants in North Carolina, adding capacity for gene-targeting therapies and automation. The company has seven factories in the state, with an eighth set to begin operations in late 2025. The U.S. drugmaker will invest $1 billion in a new Delaware plant to make biologics and Keytruda, to boost U.S. production and potentially create over 4,500 jobs. It also opened a $1-billion facility at its North Carolina site in March. Its animal health unit will invest $895 million to expand its Kansas manufacturing and R&D site, part of a broader $9 billion U.S. investment through 2028. CEO Robert Davis in July flagged minimal impact from potential tariffs in 2025, and that the company remained well-positioned due to inventory management and moving of manufacturing to the U.S. The U.S.-based biopharma firm plans to invest $900 million to expand its Ohio manufacturing facility, bringing total investment in the state to $1.4 billion and adding 750 jobs. In December, the company committed $1 billion to build a second facility in Holly Springs, North Carolina. Amgen said in September it is investing more than $600 million to build a new research and development center at its headquarters in Thousand Oaks, California. Earlier this year, the U.S. drugmaker said it had enough manufacturing capacity across its 10 U.S. sites and two distribution centers to manage potential tariff impacts and would consider shifting production to those facilities if needed. 3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads. The Danish pharmaceutical company said in August its strong U.S. manufacturing footprint positions it well for tariff challenges, describing itself as "very U.S.-centric and U.S.-focused". The U.S. drugmaker has confirmed plans to continue investing in its previously announced $10 billion expansion in the country over the next decade. It already has 11 manufacturing sites in the U.S. and has said it is "fairly insulated" from any tariff impact this year given inventory management actions. Gilead Sciences Earlier this year, the drugmaker announced $11 billion in new planned investment in the U.S. to add to its domestic manufacturing and research heft, taking its total pledged investment to $32 billion. Gilead said in September that it started work on a pharmaceutical development and manufacturing hub at its headquarters in Foster City, California, in addition to which, it is currently developing two other sites. The Indian drugmaker is expanding its U.S. manufacturing footprint by investing in capacity expansion for complex respiratory products at its advanced facilities in Fall River, Massachusetts, and Central Islip, Long Island, New York. Most investors will find it hard to answer that question with total confidence. Short of a guarantee, which no one can give you, the most successful traders stick to proven best practices without letting hype or hyper-vigilance take over their better judgment. But that doesn't mean you can't use smart shortcuts. If you're considering LLY, try chatting with WarrenAI, our powerful AI financial assistant. It's just like ChatGPT for investors, but with access to 10 years of company data, a built-in screener, Wall Street analysts' reports, and earnings call transcripts for real-time, vetted insights. Even if you end up going with your gut feeling, at least you'll know why.

Investing.com -- The U.S. Food and Drug Administration launched a new program called FDA PreCheck on Thursday to strengthen domestic pharmaceutical manufacturing and reduce reliance on foreign suppliers. Currently, more than half of pharmaceuticals distributed in the U.S. are manufactured overseas, with only 11% of active pharmaceutical ingredient (API) manufacturers for FDA-approved products based in the United States. "Our gradual overreliance on foreign drug manufacturing has created national security risks," said FDA Commissioner Marty Makary, M.D., M.P.H. "The FDA PreCheck initiative is one of many steps FDA is taking that can help reverse America’s reliance on foreign drug manufacturing and ensure that Americans have a resilient, strong, and domestic drug supply." The program was developed in response to Executive Order 14293, "Regulatory Relief to Promote Domestic Production of Critical Medicines," which directs the FDA to streamline review processes and eliminate unnecessary regulatory requirements. FDA PreCheck introduces a two-phase approach to facilitate new U.S. drug manufacturing facilities. The first phase, called Facility Readiness, provides manufacturers with more frequent FDA communication during facility design, construction, and pre-production stages. Companies are encouraged to submit comprehensive facility information through a Type V Drug Master File. The second phase, Application Submission, focuses on streamlining the Chemistry, Manufacturing, and Controls section of applications through pre-application meetings and early feedback. The FDA will host a public meeting titled "Onshoring Manufacturing of Drugs and Biological Products" on September 30, 2025, at the FDA White Oak Campus in Silver Spring, Maryland. Virtual participation will be available. The meeting will present the FDA PreCheck draft framework and include stakeholder discussions on overcoming onshoring challenges. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. With valuations skyrocketing in 2024, many investors are uneasy putting more money into stocks. Unsure where to invest next? Get access to our proven portfolios and discover high-potential opportunities. In 2024 alone, ProPicks AI identified 2 stocks that surged over 150%, 4 additional stocks that leaped over 30%, and 3 more that climbed over 25%. That's an impressive track record. With portfolios tailored for Dow stocks, S&P stocks, Tech stocks, and Mid Cap stocks, you can explore various wealth-building strategies.

US FDA Flags Violations By Granules India, Supplier Of Paracetamol.

On the heels of a production-tinged executive order earlier this month, the Trump administration is doubling down on efforts to boost medicine manufacturing in the U.S. | In a new public-private partnership,...

Pharmaceutical Hot Melt Extrusion Market growth is projected to reach USD 7.5 Billion, at a 5.89% CAGR by driving industry size, share, top company analysis, segments research, trends and forecast rep...

United States Pharmaceutical Manufacturing Equipment Market is projected to register a CAGR of 6.16% to reach USD 29.79 Billion by the end of 2032, United States Pharmaceutical Manufacturing Equipment...

By 2032, the market is expected to grow to USD 234.5 billion at a compound annual growth rate (CAGR) of 2.98% from 2025 to 2032

Pharmaceutical Equipment Market is projected to reach USD 85.0 billion by 2032, growing at a CAGR of 4.29% during the forecast period from 2025 to 2032.

A heart-wrenching story of a man taking a transplant drug exempted from a ban due to inadequate manufacturing controls. ProPublica reports

Record ground protection at pharma plants: Ensuring ESD control, product quality, and safety through best practices, industry standards, and advanced technologies.

Fill Finish Manufacturing from 2019 to 2022 and its CAGR from 2019 to 2023, and also forecasts its market size to the end of 2031 and its expected to grow with a CAGR of 8.9% from 2024 to 2031.

𝗠𝗼𝗻𝘁𝗲𝗹𝘂𝗸𝗮𝘀𝘁 𝗦𝗼𝗱𝗶𝘂𝗺 𝗠𝗮𝗿𝗸𝗲𝘁: 𝗪𝗵𝗲𝗿𝗲 𝗥𝗲𝘀𝗽𝗶𝗿𝗮𝘁𝗼𝗿𝘆 𝗖𝗮𝗿𝗲, 𝗚𝗲𝗻𝗲𝗿𝗶𝗰 𝗔𝗰𝗰𝗲𝘀𝘀 & 𝗘𝗺𝗲𝗿𝗴𝗶𝗻𝗴 𝗠𝗮𝗿𝗸𝗲𝘁𝘀 𝗔𝗿𝗲 𝗦𝗵𝗮𝗽𝗶𝗻𝗴 𝗚𝗿𝗼𝘄𝘁𝗵 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞: https://lnkd.in/dD4jk8jy The Global Montelukast Sodium Market is on a s...